Many patients with overweight or obesity discontinue GLP-1 receptor agonist therapy within 1 year, with higher discontinuation rates seen for those without type 2 diabetes.

HealthDay News — Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within one year, with higher discontinuation rates seen for those without ...

The GLP-1 medication trend has taken the health and wellness world by storm, largely hailed as a game-changer for weight loss ...

Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. | Ascletis Pharma’s ...

Two Omaha women lost more than 300 lbs. combined with injections of a GLP-1 drug, which are used increasingly for weight loss ...

Trulicity (dulaglutide) is a prescription drug that can cause weight loss in some people but is not approved for this use.

While some orthopedic and spine surgeons are divided on how medications used for weight loss, including Ozempic and Wegovy, will shape the field, it is undeniable that the drugs are playing an ...

Since GLP-1s hit the mainstream roughly two years ago, people taking the weight-loss drugs noticed their ... found a link between taking a GLP-1 receptor agonist and drinking less—but didn ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has been shown ... ability to reduce food cravings and help people achieve weight loss. Even though the study used the starting dose of ...

Roche has reported early-stage clinical data with an oral GLP-1 agonist acquired as part of ... which revealed an average weight loss of 7.3% at four weeks in the study population of obese ...